XML 39 R6.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Revision of Prior Period, Accounting Standards Update, Adjustment
Common Stock
Additional Paid In Capital
Accumulated Other Comprehensive Gain (Loss)
Accumulated Deficit
Accumulated Deficit
Revision of Prior Period, Accounting Standards Update, Adjustment
Noncontrolling Interest
Beginning Balance at Dec. 31, 2019 $ 571,039 $ 93 $ 12 $ 935,834 $ 671 $ (365,478) $ 93  
Beginning Balance, Shares at Dec. 31, 2019     125,238,142          
Issuance of common stock upon public offering, after deducting underwriters' discounts and net offering costs paid by us $ 271,839   $ 1 271,838        
Issuance of common stock upon public offering, after deducting underwriters' discounts and net offering costs paid by us, Shares     7,200,000          
Accounting Standards Update Extensible List ASC 842              
Issuance of common stock for cash upon exercise of stock options $ 21,539   $ 1 21,538        
Issuance of common stock for cash upon exercise of stock options, Shares     5,204,254          
Vesting of restricted stock units     4,500          
Share-based compensation 24,761     24,761        
Other comprehensive income (loss) 222       222      
Net loss (146,227)         (146,227)    
Ending Balance at Dec. 31, 2020 743,266   $ 14 1,253,971 893 (511,612)    
Ending Balance, Shares at Dec. 31, 2020     137,646,896          
Issuance of common stock upon exercise of common stock warrant, Shares     54,162          
Issuance of common stock for cash upon exercise of stock options 26,484     26,484        
Issuance of common stock for cash upon exercise of stock options, Shares     3,674,057          
Vesting of restricted stock units     18,750          
Share-based compensation 43,251     43,251        
Capital contributions for Digital Biotechnologies, Inc. 429     300       $ 129
Other comprehensive income (loss) (2,030)       (2,030)      
Net loss (207,298)         (207,279)   (19)
Ending Balance at Dec. 31, 2021 604,102   $ 14 1,324,006 (1,137) (718,891)   110
Ending Balance, Shares at Dec. 31, 2021     141,393,865          
Issuance of common stock for cash upon exercise of stock options $ 7,866     7,866        
Issuance of common stock for cash upon exercise of stock options, Shares 1,406,500   1,406,500          
Vesting of restricted stock units     304,637          
Share-based compensation $ 55,477     55,477        
Other comprehensive income (loss) (2,979)       (2,979)      
Net loss (200,368)         (200,191)   (177)
Ending Balance at Dec. 31, 2022 $ 464,098   $ 14 $ 1,387,349 $ (4,116) $ (919,082)   $ (67)
Ending Balance, Shares at Dec. 31, 2022     143,105,002